NCT06643390CompletedPhase 1
A Study of MK-2225 in Healthy Participants (MK-2225-003)
A Multiple Ascending Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-2225 in Healthy Participants
Source: ClinicalTrials.gov · Last updated 29 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens to different doses of MK-2225 in a person's body over time.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 14 Oct 2024
- Start date
- 21 Nov 2023
- Primary completion date
- 14 Jul 2025
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT06643390
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 32
- From 21 Nov 2023 to the primary completion date, 14 Jul 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
- History of hypersensitivity to the MK-2225 drug substance, its inactive ingredients or the placebo (normal saline)
Other
- The key exclusion criteria include but are not limited to the following:
Who the study is looking for
- The key inclusion criteria include but are not limited to the following:
- Is in good health before randomization
- Body Mass Index (BMI) ≤32 kg/m\^2, inclusive
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Pharmacology of Miami (Site 0002) Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| Bio-Kinetic Clinical Applications, LLC dba QPS-MO (Site 0004) Coordinator of this site? Confirm its status | Springfield | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.